CLINICAL PRACTICE;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG ACTIVITY;
DRUG BLOOD LEVEL;
DRUG EFFECT;
DRUG EFFICACY;
EDITORIAL;
HUMAN;
MEDICAL PRACTICE;
PRIORITY JOURNAL;
SCHIZOPHRENIA;
STATISTICAL SIGNIFICANCE;
Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication
Nesvag R Hendset M Refsum H et al. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 2006 114: 21 26.
Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
Schotte A Janssen PFM Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. J Psychopharmacol 1996 124: 57 73.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
Lieberman JA McEvoy JP Swartz MS et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005 353: 1209 1223.
Risperidone in acutely exacerbated schizophrenia: Dosing strategies and plasma levels
Lane HY Chiu WC Chou JC et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000 61: 209 214.
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenia patients
Nyberg S Eriksson B Oxenstierna G et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenia patients. Am J Psychiatry 1999 156: 869 875.
Serum concentrations and side effects in psychiatric patients during risperidone therapy
Olesen OV Licht RW Thomsen E et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998 20: 380 384.
Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone
Aravagiri M Marder SR Nuechterlein KH et al. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit 2003 25: 657 664.
Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic
Kane JM Eerdekens M Lindenmayer JP et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003 160: 1125 1132.
Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic
Fleischhacker WW Eerdekens M Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003 64: 1250 1257.
doi: 10.1017/S1461145705006309, published online by Cambridge University Press 23 November 2005.
Taylor DM Young C Patel MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 2005 doi: 10.1017/S1461145705006309, published online by Cambridge University Press 23 November 2005.
Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: Evidence from a routine therapeutic drug monitoring service
Castberg I Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit 2005 27: 103 106.
Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia
Gefvert O Eriksson B Persson P et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005 8: 27 36.
